Literature DB >> 11470000

New developments in the understanding of cholera.

T Butler1.   

Abstract

Recent advances in prevention and treatment of cholera have occurred in the areas of vaccine testing, modifications of oral-rehydration solutions (ORS), and antimicrobial treatment. Oral vaccines consisting of killed whole bacterial cells (WC) with and without the B-subunit of cholera toxin (BS) were shown to be effective in large trials in Bangladesh, Peru, and Vietnam. However, the trials did not resolve whether two or three doses of vaccine are required and whether BS adds significantly to the immune protection of WC. Live, attenuated bacterial vaccines that are immunogenic and have been shown protective in human volunteer studies are candidates for future field trials. Rehydration of patients is a life- saving effort. The best ORS contains rice powder in place of glucose, and solutions with reduced osmolarity (245 mOsm/L, sodium 75 mEq/L) are as effective as standard ORS. Ciprofloxacin in a single dose is effective in adults, and erythromycin or ampicillin in multiple doses is effective in children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470000     DOI: 10.1007/s11894-001-0054-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  49 in total

Review 1.  Current status of cholera and rise of novel mucosal vaccine.

Authors:  T Yamamoto
Journal:  Jpn J Infect Dis       Date:  2000-10       Impact factor: 1.362

2.  Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.

Authors:  D N Taylor; V Cárdenas; J Perez; R Puga; A M Svennerholm
Journal:  Am J Trop Med Hyg       Date:  1999-12       Impact factor: 2.345

3.  Effect of granisetron on cholera toxin-induced enteric secretion.

Authors:  J L Turvill; M J Farthing
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

4.  Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.

Authors:  J Clemens; M Rao; D Sack; F Ahmed; M R Khan; J Chakraborty; B Kay; S Huda; M Yunus; F van Loon
Journal:  Am J Epidemiol       Date:  1995-10-01       Impact factor: 4.897

5.  Oral ciprofloxacin in the treatment of cholera.

Authors:  E Gotuzzo; C Seas; J Echevarria; R Ruiz; C Carrillo
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double-blind clinical trial. CHOICE study group.

Authors:  N H Alam; R N Majumder; G J Fuchs
Journal:  Lancet       Date:  1999-07-24       Impact factor: 79.321

7.  New insights on the emergence of cholera in Latin America during 1991: the Peruvian experience.

Authors:  C Seas; J Miranda; A I Gil; R Leon-Barua; J Patz; A Huq; R R Colwell; R B Sack
Journal:  Am J Trop Med Hyg       Date:  2000-04       Impact factor: 2.345

8.  Food-based oral rehydration salt solution for acute childhood diarrhoea.

Authors:  A M Molla; A Molla; S K Nath; M Khatun
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

9.  The effect of L-glutamine on salt and water absorption: a jejunal perfusion study in cholera in humans.

Authors:  F P van Loon; A K Banik; S K Nath; F C Patra; M A Wahed; D Darmaun; J F Desjeux; D Mahalanabis
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-05       Impact factor: 2.566

10.  Multicentre evaluation of reduced-osmolarity oral rehydration salts solution. International Study Group on Reduced-osmolarity ORS solutions.

Authors: 
Journal:  Lancet       Date:  1995-02-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.